Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Mulder

Showing results (81-90 of 147) with videos related to

Pageof 15
Sort By:
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|December 15, 1995
Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infectionM H Godfried, T van der Poll, J W Mulder, et al.
Therapeutic Drug Monitoring|May 22, 2001
Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapineR P van Heeswijk, A I Veldkamp, J W Mulder, et al.
AIDS (London, England)|July 14, 2000
Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot studyR P van Heeswijk, A I Veldkamp, J W Mulder, et al.
The Journal of Infectious Diseases|January 1, 1992
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjectsC A Boucher, E O'Sullivan, J W Mulder, et al.
Cancer Chemotherapy and Pharmacology|May 13, 1999
Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma--drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report studyV R Nannan Panday, R M Hoetelmans, R P van Heeswijk, et al.
Therapeutic Drug Monitoring|January 22, 2002
Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapineA I Veldkamp, R P van Heeswijk, J W Mulder, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications|June 9, 1999
Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detectionA I Veldkamp, R P van Heeswijk, R M Hoetelmans, et al.
Lancet (London, England)|November 26, 1994
Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteinsJ W Mulder, P M Kruyt, M Sewnath, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications|November 26, 1999
Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detectionA I Veldkamp, R P van Heeswijk, P L Meenhorst, et al.
The Journal of Infectious Diseases|April 1, 1994
Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infectionM H Godfried, T van der Poll, G J Weverling, et al.
Pageof 15

Showing results (81-90 of 147) with videos related to

Sort By:
Pageof 15
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|December 15, 1995
Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infectionM H Godfried, T van der Poll, J W Mulder, et al.
Therapeutic Drug Monitoring|May 22, 2001
Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapineR P van Heeswijk, A I Veldkamp, J W Mulder, et al.
AIDS (London, England)|July 14, 2000
Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot studyR P van Heeswijk, A I Veldkamp, J W Mulder, et al.
The Journal of Infectious Diseases|January 1, 1992
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjectsC A Boucher, E O'Sullivan, J W Mulder, et al.
Cancer Chemotherapy and Pharmacology|May 13, 1999
Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma--drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report studyV R Nannan Panday, R M Hoetelmans, R P van Heeswijk, et al.
Therapeutic Drug Monitoring|January 22, 2002
Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapineA I Veldkamp, R P van Heeswijk, J W Mulder, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications|June 9, 1999
Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detectionA I Veldkamp, R P van Heeswijk, R M Hoetelmans, et al.
Lancet (London, England)|November 26, 1994
Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteinsJ W Mulder, P M Kruyt, M Sewnath, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications|November 26, 1999
Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detectionA I Veldkamp, R P van Heeswijk, P L Meenhorst, et al.
The Journal of Infectious Diseases|April 1, 1994
Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infectionM H Godfried, T van der Poll, G J Weverling, et al.
Pageof 15